Please login to the form below

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C. 

The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.

http://www.researchpartnership.com/news/2017/01/access-and-elimination-the-future-of-daas-in-hepatit...



25th January 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.
Research Partnership
News:
Senior Analytics Specialist joins Research Partnership
Research Partnership
Article:
All change – how untangling human behaviour can encourage better health
Research Partnership
Webinar:
Understanding changing digital behaviours: Insights needed for an effective omnichannel strategy
Research Partnership
News:
Therapy Watch COVID-19 tracker
Research Partnership
Events:
Patient Centricity and Engagement Conference 2021
Research Partnership